Matthieu Delaye1,2, Mélanie Try3,4, Adrien Rousseau3,5, Marie-Camille Lafargue3,6, Arnaud Saillant3,7, Matthieu Bainaud3,7, Marine Andreani3,8, David Rozenblat3,9, Luca Campedel3,10, Pauline Corbaux3,11, Corinne Isnard-Bagnis3,12. 1. Department of Medical Oncology and Cellular Therapy, Tenon Hospital (Public Assistance Paris Hospitals, AP-HP), 4 rue de la Chine, Paris, France. matthieu.delaye@aphp.fr. 2. Groupe de Recherche Interdisciplinaire Francophone en Onco-Néphrologie (GRIFON), 47-83 boulevard de l'hôpital, 75013, Paris, France. matthieu.delaye@aphp.fr. 3. Groupe de Recherche Interdisciplinaire Francophone en Onco-Néphrologie (GRIFON), 47-83 boulevard de l'hôpital, 75013, Paris, France. 4. Nephrology Department, Kremlin Bicêtre University Hospital, Assistance Publique Hôpitaux de Paris, Le Kremlin Bicêtre, France. 5. Intensive Care Unit, Gustave Roussy, Villejuif, France. 6. University of Paris, Paris, France. 7. Medical Oncology, Poitiers University Hospital, Poitiers, France. 8. Department of Nephrology-Dialysis-Transplantation, Centre Hospitalier Universitaire de Nice, Nice, France. 9. Nephrology Department, Hospital Henri Mondor, Creteil, France. 10. AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, institut universitaire de cancérologie, département d'oncologie médicale, CLIP2, Galilée Paris, France. 11. Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Lyon, France. 12. Nephrology Department, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Abstract
INTRODUCTION: Renal events are common in cancer patients and malignancy is a prevalent complication in both patients transplanted and under kidney replacement therapy (KRT). In recent years, onco-nephrology has been developed as a subspecialty whose scope has not been well established yet. The aim of our study was to assess resident and senior physicians' knowledge and expectations about onco-nephrology. METHODS AND MATERIALS: Two anonymous self-administered online questionnaires were developed by a multidisciplinary team and distributed to French residents and senior physicians. RESULTS: Two hundred twenty-eight physicians answered the survey, including 128 (56%) nephrologists, of which 98 (43%) were senior physicians and 130 (57%) were residents. Nephrologists rated their confidence in their ability to face onco-nephrological situation at 6/10 (interquartile range (IQR) 4.0-7.0) and oncologists at 6.0/10 (5.0-7.0). Managing cancer drugs in patients on KRT or in transplanted patients and discussion about introducing dialysis in cancer patients were designated as the most challenging topics. Asking if they had received appropriate learning, residents' median agreement was ranked at 3.0/10 (2.0-4.0). Forty-six percent of the respondents considered available resources as not appropriate. Specialized onco-nephrology consultations were accessible for 21% of the respondents. Finally, respondents thought there is a strong need for a national working group (8.3/10) with 87% of them expecting new reliable guidelines. CONCLUSION: The present survey revealed physicians' expectations about onco-nephrology implementation in France. An appropriate answer could be the creation of a national working group. Therefore, GRIFON (Groupe de Recherche Interdisciplinaire en OncoNéphrologie) has recently been created.
INTRODUCTION: Renal events are common in cancer patients and malignancy is a prevalent complication in both patients transplanted and under kidney replacement therapy (KRT). In recent years, onco-nephrology has been developed as a subspecialty whose scope has not been well established yet. The aim of our study was to assess resident and senior physicians' knowledge and expectations about onco-nephrology. METHODS AND MATERIALS: Two anonymous self-administered online questionnaires were developed by a multidisciplinary team and distributed to French residents and senior physicians. RESULTS: Two hundred twenty-eight physicians answered the survey, including 128 (56%) nephrologists, of which 98 (43%) were senior physicians and 130 (57%) were residents. Nephrologists rated their confidence in their ability to face onco-nephrological situation at 6/10 (interquartile range (IQR) 4.0-7.0) and oncologists at 6.0/10 (5.0-7.0). Managing cancer drugs in patients on KRT or in transplanted patients and discussion about introducing dialysis in cancer patients were designated as the most challenging topics. Asking if they had received appropriate learning, residents' median agreement was ranked at 3.0/10 (2.0-4.0). Forty-six percent of the respondents considered available resources as not appropriate. Specialized onco-nephrology consultations were accessible for 21% of the respondents. Finally, respondents thought there is a strong need for a national working group (8.3/10) with 87% of them expecting new reliable guidelines. CONCLUSION: The present survey revealed physicians' expectations about onco-nephrology implementation in France. An appropriate answer could be the creation of a national working group. Therefore, GRIFON (Groupe de Recherche Interdisciplinaire en OncoNéphrologie) has recently been created.
Authors: V Launay-Vacher; M Aapro; G De Castro; E Cohen; G Deray; M Dooley; B Humphreys; S Lichtman; J Rey; F Scotté; H Wildiers; B Sprangers Journal: Ann Oncol Date: 2015-03-03 Impact factor: 32.976
Authors: Melina Arnold; Mark J Rutherford; Aude Bardot; Jacques Ferlay; Therese M-L Andersson; Tor Åge Myklebust; Hanna Tervonen; Vicky Thursfield; David Ransom; Lorraine Shack; Ryan R Woods; Donna Turner; Suzanne Leonfellner; Susan Ryan; Nathalie Saint-Jacques; Prithwish De; Carol McClure; Agnihotram V Ramanakumar; Heather Stuart-Panko; Gerda Engholm; Paul M Walsh; Christopher Jackson; Sally Vernon; Eileen Morgan; Anna Gavin; David S Morrison; Dyfed W Huws; Geoff Porter; John Butler; Heather Bryant; David C Currow; Sara Hiom; D Max Parkin; Peter Sasieni; Paul C Lambert; Bjørn Møller; Isabelle Soerjomataram; Freddie Bray Journal: Lancet Oncol Date: 2019-09-11 Impact factor: 41.316
Authors: Nathan R Hill; Samuel T Fatoba; Jason L Oke; Jennifer A Hirst; Christopher A O'Callaghan; Daniel S Lasserson; F D Richard Hobbs Journal: PLoS One Date: 2016-07-06 Impact factor: 3.240